Quantbot Technologies LP Makes New $29,000 Investment in Health Catalyst, Inc. (NASDAQ:HCAT)

Quantbot Technologies LP acquired a new position in Health Catalyst, Inc. (NASDAQ:HCAT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,131 shares of the company’s stock, valued at approximately $29,000.

A number of other hedge funds have also made changes to their positions in the business. Point72 Asset Management L.P. raised its holdings in shares of Health Catalyst by 69.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after buying an additional 211,805 shares during the period. Impax Asset Management Group plc grew its position in Health Catalyst by 7.7% in the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after acquiring an additional 195,525 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Health Catalyst by 4.9% during the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after purchasing an additional 66,896 shares during the period. State Street Corp lifted its position in shares of Health Catalyst by 2.5% during the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after purchasing an additional 28,251 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Health Catalyst in the fourth quarter valued at $110,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Trading Down 4.4 %

Shares of NASDAQ HCAT opened at $4.33 on Wednesday. The firm has a market capitalization of $304.01 million, a PE ratio of -3.21 and a beta of 1.41. Health Catalyst, Inc. has a one year low of $3.76 and a one year high of $9.24. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average price of $4.98 and a two-hundred day moving average price of $6.80.

Insider Transactions at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 16,902 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the transaction, the chief operating officer now owns 216,250 shares of the company’s stock, valued at $977,450. This represents a 7.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Linda Llewelyn sold 6,442 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $5.80, for a total transaction of $37,363.60. Following the completion of the sale, the insider now directly owns 92,260 shares in the company, valued at $535,108. This trade represents a 6.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,530 shares of company stock valued at $299,572 in the last three months. Corporate insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on HCAT. Royal Bank of Canada decreased their price objective on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Thursday, February 27th. Stephens reduced their price target on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, March 6th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective on the stock in a report on Wednesday, January 8th. Citigroup reduced their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Finally, Stifel Nicolaus decreased their price target on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a research report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.27.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.